Nirmal Bang

Nirmal Bang, one of the leading stock broking companies in India, caters to retail and institutional clients by offering them a range of financial products and services, including equities, derivatives, commodities, currency derivatives, mutual funds, IPOs, insurance, depository services and PMS.

Nirmal Bang is drawn from a diversity of professional backgrounds, and blend of experience, skill and dedication is shared with its clients. Nirmal Bang emphasizes adequate, thorough research local and world-wide developments, balancing these with the astute discovery of intrinsic values, synergies and growth. The aim is simply to help the investors to maximize their returns.

A Relationship Beyond Broking

External broker reports(aggregated public sources), Nirmal Bang

External broker reports(aggregated public sources)

Equity Bottom-Up

<div>
<div>
<div>
<div>
<ul>
<li>3QFY22 performance: GILL’s 3QFY22 revenue grew by 5.6% YoY to Rs5.7bn (vs our est. of Rs5.9bn).</li>
</ul>
<div>
<div>
<div>
<div>
<ul>
<li>3QFY22 segmental performance: In terms of revenue, while the Grooming segment (76.1% of sales in 9MFY22) grew by 8.9% YoY (largely in line with our estimate; 3-year CAGR of 5.5%), Oral Care disappointed with a decline of 5.1% YoY (a drop of 12% even on QoQ basis; 3-year CAGR of 12.2%).</li>
</ul>
<div>
<div>
<div>
<div>
<ul>
<li>9MFY22 performance: Revenue was up by 8.3% YoY while EBITDA &amp; PAT were down by 9.2% YoY &amp; 16.8% YoY, respectively.</li>
</ul>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>






3QFY22 performance: GILL’s 3QFY22 revenue grew by 5.6% YoY to Rs5.7bn (vs our est. of Rs5.9bn).






3QFY22 segmental performance: In terms of revenue, while the Grooming segment (76.1% of sales in 9MFY22) grew by 8.9% YoY (largely in line with our estimate; 3-year CAGR of 5.5%), Oral Care disappointed with a decline of 5.1% YoY (a drop of 12% even on QoQ basis; 3-year CAGR of 12.2%).






9MFY22 performance: Revenue was up by 8.3% YoY while EBITDA &amp; PAT were down by 9.2% YoY &amp; 16.8% YoY, respectively.













Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Gillette India - Mixed Bag; Limited Upside Leads to Rating Downgrade